Document is current

Article History

Received: 13 September 2024

Accepted: 17 December 2024

First Online: 11 January 2025

Declarations

:

: François Barbier have received over the past three years lecture and consulting fees from MSD, lecture fees for BioMérieux, and conference invitation from Pfizer, not related to the submitted work; Jean-François Timsit reported advisory boards participation for Merck, Gilead, Beckton-Dickinson, Pfizer, Shinogi, Medimune, Paratek, research grants from Merck, Pfizer, Thermofischer; Niccolò Buetti received a post.doc Mobility grant (2021) from the Swiss National Science Foundation (Grant Number: P4P4PM_194449); Dafna Yahav is an Editorial Board member of Infectious Diseases and Therapy. Dafna Yahav was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; Tomer Hoffman, Ili Margalit, Alexis Tabah, Stephane Ruckly, Pierre Singer, Virginie Prendki, and Nasreen Hassoun-Kheir declare no conflict of interest.

: The EUROBACT-2 trial was initially approved by the Research Ethics Committee of Royal Brisbane & Women’s Hospital, Queensland, Australia (LNR/2019/QRBW/48376). The study was further approved by the institutional ethics review boards at each participating site (for further details on the national coordinators, scientific committees, and participating ICUs, see the Supplementary Information of Tabah et al. []). The study was conducted in accordance with the ethical standards of the committees responsible on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975.